60 Degrees Pharma Deck Adds Chronic-Study Screening Data and 2027 sNDA Timeline
SXTP is trading near its 52-week low of $0.812 (7.3% above the low) on light trading volume (0.1× avg).
Summary
60 Degrees' updated investor deck discloses slow chronic-study enrollment (2/9 genus-positive, 0/9 species-positive) alongside a 27% lower retreatment hazard per doubling of treatment duration in published relapsing cases, and lays out an sNDA filing in April/May 2027 with a potential priority-voucher decision in May/June 2027.
Key Events · Product Development and Regulatory · SXTP
-
Investor Deck Updated at ILADS 2026
An 8-K furnishes an investor presentation dated October 23, 2026 covering tafenoquine across acute, relapsing and chronic babesiosis; no new financing or corporate terms are disclosed.
-
Chronic Study Screening Falls Short
B-FREE has screened nine patients: 2/9 genus dPCR positive, 0/9 B. microti NAT positive and 0/9 Mayo species-specific PCR positive, so no enrolled patient has yet qualified for the primary per-protocol analysis; recruitment is described as slow.
-
Relapsing-Case Analysis Shows Duration Effect
Across 45 published relapsing-babesiosis cases (79 evaluable episodes, 40 patients, 49 retreatments), each doubling of uninterrupted treatment duration was associated with a 27% lower retreatment hazard (HR 0.73, 95% CI 0.58-0.93).
-
Regulatory Path Targets 2027 Filing
Hospital study unblinding is planned for January 2027, a pre-sNDA meeting for late January 2027, sNDA filing April/May 2027, and a potential CNPV decision May/June 2027 under the accelerated path; the base plan puts launch in Q1 2028.
Analysis · SXTP · Life Sciences
The deck itself is not new news — the October 6, 2026 8-K already told investors enrollment closed at 30 patients. What is new is the detail underneath: the chronic B-FREE study has screened nine patients with 2/9 genus dPCR positives but 0/9 species-specific positives, so nobody has yet qualified for the primary endpoint and recruitment is described as slow. The relapsing-disease reanalysis (45 cases, 79 episodes) reports a 27% lower retreatment hazard per doubling of uninterrupted treatment, and the tafenoquine-atovaquine cases show 6/7 responses versus ~1.65 expected. Against a going-concern backdrop with cash previously disclosed as sufficient only through early October 2026, the value here is the regulatory calendar: hospital unblinding January 2027, pre-sNDA meeting late January 2027, sNDA filing April/May 2027, and a potential CNPV decision May/June 2027. The company still needs financing to reach those dates, and the chronic program is explicitly hypothesis-generating rather than pivotal.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.6% of the 1590 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SXTP was trading at $0.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1M. The 52-week trading range was $0.81 to $8.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.